Pharma channel feed

HHS fo­cus­es on 'trans­paren­cy' in third-round IRA ne­go­ti­a­tion guid­ance

Last month
Law

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

Last month
Manufacturing

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Last month

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Last month
People

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Last month

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Last month
Law

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

Last month
Law

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Last month
Manufacturing

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Last month

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Last month
R&D

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Last month
Manufacturing

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

Last month
Manufacturing

Il­lu­mi­na con­firms SEC has closed in­ves­ti­ga­tion in­to $8B Grail deal

Last month
Diagnostics

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

Last month

Il­lu­mi­na fore­casts $85M in tar­iff costs, de­crease in Chi­na sales

Last month
Diagnostics

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

Last month
Law

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

Last month
FDA+

FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment

Last month
FDA+

FDA will con­vene vac­cine ad­vi­sors to dis­cuss Covid strain up­dates

Last month
FDA+

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

Last month
R&D
Manufacturing

Te­va plans staff cuts as it com­mits to ac­cel­er­at­ing growth

Last month
Manufacturing

PhRMA says tar­iffs are 'not the an­swer' as in­dus­try trade probe clos­es for com­ments

Last month
Manufacturing

FDA's ODAC will re­view drugs for four dif­fer­ent can­cers at meet­ing in May

Last month
FDA+

Avadel can pur­sue la­bel ex­pan­sion for nar­colep­sy drug Lum­ryz af­ter court rul­ing

Last month
Law
First page Previous page 3456789 Next page Last page
A service from the Financial Times